Showing results (141-150 of 219) with videos related to
Sort By:
Pageof 22
Frontiers in Oncology|October 17, 2022
Intermittent MEK inhibition for the treatment of metastatic uveal melanomaShaheer Khan, Sapna P Patel, Alexander N Shoushtari, et al.Investigational New Drugs|May 13, 2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsMark Andrew Dickson, Dana E Rathkopf, Richard D Carvajal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibitionLisa Zimmer, Uwe Hillen, Elisabeth Livingstone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2015
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z Horvat, Nelly G Adel, Thu-Oanh Dang, et al.The Oncologist|June 12, 2016
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First MetastasisDeborah Kuk, Alexander N Shoushtari, Christopher A Barker, et al.Sarcoma|June 16, 2015
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue SarcomaMark A Dickson, David R D'Adamo, Mary L Keohan, et al.Investigational New Drugs|June 29, 2022
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumorsTodd Bauer, Byong Chul Cho, Rebecca Heist, et al.Cancer Immunology Research|March 5, 2015
Impact of NRAS mutations for patients with advanced melanoma treated with immune therapiesDouglas B Johnson, Christine M Lovly, Marisa Flavin, et al.Investigational New Drugs|April 14, 2021
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumorsGerald S Falchook, Marc Peeters, Sylvie Rottey, et al.The Oncologist|August 22, 2018
A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath TumorsDavid R D'Adamo, Mark A Dickson, Mary L Keohan, et al.Pageof 22